Drug intelligence / Profile preview

abz-495

Development stage: Preclinical
Lead developer: Abzyme Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

Abz-495 is a bispecific T-cell engager (BiTE) drug candidate developed by Abzyme Therapeutics. It targets the CD3 molecule on T cells and acts as a CD3 stimulant, aiming to activate T cells for anti-tumor immune responses. The primary therapeutic area under investigation is neoplasms (cancers). As of June 2025, its highest development status is preclinical[1][5]. No clinical trials or regulatory approvals have been reported.

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on abz-495.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on abz-495.

Explore the full profile